[Form 4] GLOBUS MEDICAL INC Insider Trading Activity

Rhea-AI Filing Summary

Keith W. Pfeil, identified as President, CEO and a director of Globus Medical (GMED), received a grant of 40,000 stock options on 07/18/2025 with an exercise price of $56.34. The options are exercisable into 40,000 shares of Class A common stock and are held directly. Vesting begins on 07/18/2025 and occurs over four years: one-fourth vests on 07/18/2026 and the remainder vests ratably monthly over the following 36 months. The form reports the grant as an acquisition (A) of derivative securities (stock options).

Positive

• 40,000 option grant to the CEO/director is disclosed transparently, including strike price and vesting schedule
• Four-year vesting with a one-year cliff aligns executive incentives with longer-term performance

Negative

• Potential dilution of 40,000 shares if options are exercised
• Exercise price of $56.34 requires stock appreciation above that level for intrinsic value

Insights

Corporate Governance Expert

TL;DR: A standard multi-year option grant to the CEO/director that ties compensation to long-term equity performance.

The 40,000-option grant to Keith W. Pfeil reflects typical executive equity compensation structure with a four-year vesting schedule and monthly ratable vesting after the first-year cliff. As reported, the award is direct and exercisable into 40,000 shares at a $56.34 strike, which creates long-term alignment between the executive and shareholders if the stock appreciates above the strike. This disclosure is routine and provides transparency on insider holdings and potential future dilution.

Compensation Analyst

TL;DR: The grant size and four-year vesting are consistent with retention and performance incentives for a CEO-level executive.

Detailing vesting milestones (25% after one year, monthly thereafter) signals a retention focus. The exercise price is explicit at $56.34 and the options expire in 2035, giving a ten-year term from grant. The direct ownership of 40,000 underlying shares is material for modeling potential dilution and future insider exercising behavior, but on its face is not unusually large without broader pay context.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeil Keith W

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$56.34	07/18/2025		A		40,000		(1)	07/18/2035	Class A Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. These options were granted on July 18, 2025, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on July 18, 2026, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

	/s/ Kelly G. Huller, Attorney-in-Fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who received the option grant reported on Form 4 for GMED?

The reporting person is Keith W. Pfeil, identified as President, CEO and a director of Globus Medical (GMED).

What was granted to Keith W. Pfeil and on what date?

He was granted 40,000 stock options on 07/18/2025.

What is the exercise price and underlying security for the options?

The options have an exercise price of $56.34 and are exercisable into Class A common stock (40,000 shares underlying).

How do the options vest?

Vesting occurs over four years with one-fourth vesting on 07/18/2026 and the remainder vesting ratably each month over the next 36 months.

Are the reported options held directly or indirectly?

The Form 4 lists the ownership form as Direct (D).